Journals / Yeni Üroloji Dergisi / 2016 / Cilt: 11 - Sayı: 3

Comparison of serum c-reactive protein levels between benign prostate hyperplasia and prostate cancer in patients undergoing prostate biopsy

Prostat biyopsisi uygulanan hastalarda serum c-reaktif protein düzeylerinin benign prostat hiperplazisi ve prostat kanseri arasında karşılaştırılması

Pages
12–17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

İscompared with each other using Wilcoxon-Mann tatisiksel değerlendirmede p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: It has been argued that prostate cancer may have an association with inflammation.
📊
Key Findings & Data:We compared serum CRP values between benign prostate hyperplasia BPH and pılmış hastalarda biyopsi sonucu benign prostat hiprostate cancer PCa diagnosed by prostate biopperplazisi BPH ve prostat kanseri PCa gelenler sy performed in patients with a tPSA level greater than 4.0 ng/dl.
💡
Conclusion & Impact:İscompared with each other using Wilcoxon-Mann tatisiksel değerlendirmede p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:PSA · Prostate biopsy · CRP

Abstract

Objective: It has been argued that prostate cancer may have an association with inflammation. Prostate specific antigen is widely used for diagnosis, treatment, and follow-up of prostate cancer. C-reactive protein is a widely utilized marker of inflammation. We compared serum CRP values between benign prostate hyperplasia BPH and pılmış hastalarda biyopsi sonucu benign prostat hiprostate cancer PCa diagnosed by prostate biopperplazisi BPH ve prostat kanseri PCa gelenler sy performed in patients with a tPSA level greater than 4.0 ng/dl. Material and Methods: Serum CRP and sedimentation rate were retrospectively assessed in 182 patients who had a tPSA level above 4.0 ng/dl and were scheduled to undergo prostate biopsy. Pathology results of 175 patients could be accessed. CRP levels of patients with BPH and PCa were testleri yöntemleriyle çalışılarak karşılaştırıldı. İscompared with each other using Wilcoxon-Mann tatisiksel değerlendirmede p

Özet

olabileceği düşünülmektedir. Prostat spesifik antijen prostat kanserinin tanı, tedavi ve takiplerde yaygın olarak kullanılmaktadır. C-reaktif protein inflamasyonda yaygın kullanılan bir belirteçtir. Çalışmamızda tPSA’sı >4,0 ng/ml olan ve biyopsi yapılmış hastalarda biyopsi sonucu benign prostat hiperplazisi BPH ve prostat kanseri PCa gelenler arasındaki serum CRP değerlerini karşılaştırdık. Gereç ve Yöntemler: tPSA >4,0 ng/dl olan ve biyopsiye karar verilen 182 hastada serum CRP ve sedimentasyon hızlarına bakıldı. Retrospektif değerlendirme yapıldı. 175 hastanın patolojik verilerine ulaşıldı. BPH ve PCa arasındaki CRP’ler Wilcoxon-Mann Whitney U ve Kruskal Wallis testleri yöntemleriyle çalışılarak karşılaştırıldı. İstatisiksel değerlendirmede p

🔖

Cite This Article

AYYILDIZ, S. N., BENLİ, E., ÇIRAKOĞLU, A., AYYILDIZ, A. (2016). Comparison of serum c-reactive protein levels between benign prostate hyperplasia and prostate cancer in patients undergoing prostate biopsy. Yeni Üroloji Dergisi, Cilt: 11 - Sayı: 3, 12–17. https://ajindex.com/articles/337200

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory meta- static prostate cancer. J Clin Oncol 2003; 21: 1232-7.
  2. Ayyıldız SN, Ayyıldız A. Prostat kanseri tanısında PSA, PSA türevleri, ProPSA ve prostat sağlık indeksi. Turk J Urol 2014; 40: 82-8.
  3. Liu Z-Q, Chu L, Fang J-M, et al. Prognostic role of C-re- active protein in prostate cancer: a systematic review and meta-analysis. Asian J Androl 2014; 16: 467-471.
  4. Graff JN, Beer TM. Editorial. The role of C-reactive protein in prostate cancer. Cancer 2013; 15: 3262. Aletaha D, Smolen J. The simplified disease activity index (SDAI) and clinical disease activity index CDAI: a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005; 23: 100-S108. Young B, Gleeson M, Cripps AW. C-reactive protein: a criti- cal review. Pathology 1991; 23:118-124.
  5. Mantovani A, Allavena P, Sica A, et al. Cancer-related in- flammation. Nature 2008; 454: 36-44.
  6. Hurlimann J, Thorbecke GJ, Hochwald GM. The liver as the site of C-reactive protein formation. J Exp Med 1966; 123: 365-78.
  7. Guo YZ, Pan L, Du CJ, et al. Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies. Asian Pac J Cancer Prev 2013; 14: 243-8.
  8. Yu Q, Yu XF, Zhang SD, et al. Prognostic role of C-reactive protein in gastric cancer: a meta-analysis. Asian Pac J Can- cer Prev 2013; 14: 5735-40.
  9. Elsberger B, Lankston L, McMillan DC, et al. Presence of tu- moural C-reactive protein correlates with progressive pros- tate cancer. Prostate Cancer Prostatic Dis 2011; 14: 122-8.
  10. Sox HC Jr, Liang MH. The erythrocyte sedimentation rate: guidelines for rational use. Ann Intern Med 1986; 104: 515- 523. Mimeault M, Johansson SL, Batra SK. Pathobiological im- plications of the expression of EGFR, pAkt, NF-KB and MIC-1 in prostate cancer stem cells and their progenies. PloS ONE 2012; 7: 31919.
  11. Ozden F, Saygin C, Uzunaslan D, et al. Expression of MMP- 1, MMP-9 and TIMP-2 in prostate carcinoma and their in- fluence on prognosis and survival. J Cancer Res Clin Oncol 2013; 139: 1373-82.
  12. Mengus C, Le Magnen C, Trella E, et al. Elevated levels of circulating IL-7 and IL-15 in patients with early stage pros- tate cancer. J Transl Med 2011; 9: 162-168.
  13. Saito K, Kihara K. Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes. Int J Urol 2013; 20: 161-71.
  14. Allin KH, Nordesgaard BG. Elevated C-reactive protein in the diagnosis